Literature DB >> 21474325

[177Lu]DOTA-anti-CD20: labeling and pre-clinical studies.

Paola F Audicio1, Gustavo Castellano, Marcos R Tassano, Maria E Rezzano, Marcelo Fernandez, Eloisa Riva, Ana Robles, Pablo Cabral, Henia Balter, Patricia Oliver.   

Abstract

Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin's Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with (177)Lu through a simple method. [(177)Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. Monte Carlo simulation showed high doses deposited on a spheroid tumor mass model. This method seems to be an appropriate alternative for the production of [(177)Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21474325     DOI： 10.1016/j.apradiso.2011.01.026

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  6 in total

Review 1.  Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with 90Y or 177Lu.

Authors:  Urszula Karczmarczyk; Agnieszka Sawicka; Piotr Garnuszek; Michał Maurin; Wioletta Wojdowska
Journal:  J Med Chem       Date:  2022-04-20       Impact factor: 8.039

Review 2.  The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.

Authors:  Evan D Read; Peter Eu; Peter J Little; Terrence J Piva
Journal:  Target Oncol       Date:  2014-05-29       Impact factor: 4.493

3.  An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.

Authors:  Parul Thakral; Suhas Singla; Madhav Prasad Yadav; Atul Vasisht; Atul Sharma; Santosh Kumar Gupta; C S Bal; Arun Malhotra
Journal:  Indian J Med Res       Date:  2014-04       Impact factor: 2.375

4.  Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.

Authors:  Nazila Gholipour; Amir Reza Jalilian; Ali Khalaj; Fariba Johari-Daha; Kamal Yavari; Omid Sabzevari; Ali Reza Khanchi; Mehdi Akhlaghi
Journal:  Daru       Date:  2014-07-29       Impact factor: 3.117

5.  Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.

Authors:  Mythili Kameswaran; Usha Pandey; Ashutosh Dash; Grace Samuel; Meera Venkatesh
Journal:  Indian J Med Res       Date:  2016-01       Impact factor: 2.375

6.  Development of DOTA-Rituximab to be Labeled with 90Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma.

Authors:  Fariba Johari Doha; Siyavash Rahmani; Pedram Rikhtechi; Samira Rasaneh; Zahra Sheikholislam; Soraya Shahhosseini
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.